切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2008, Vol. 02 ›› Issue (06) : 34 -37. doi: 10.3877/cma.j.issn.1674-0793.2008.06.014

论著

乳腺癌组织中HER2、ERα、ERβ、PR的表达及其相关性分析
王佳妮1, 刘仁斌1,(), 梁惠珍2, 周兴华1, 王深明1   
  1. 1.510080 广州,中山大学附属第一医院乳腺外科
    2.510080 广州,中山大学附属第一医院病理科
  • 收稿日期:2008-08-12 出版日期:2008-12-01
  • 通信作者: 刘仁斌
  • 基金资助:
    国家自然科学基金(30672410)广州市科技局国际合作项目(2007Z3-I0021)

Expression of HER2, ERα, ERβ and PR in breast cancer and their clinical significance

Jiani WANG1, Ren-bin LIU1,(), Hui-zhen LIANG1, Xing-hua ZHOU1, Shen-ming WANG1   

  1. 1.Department of breast surgery, the first affiliated hospital of Sun Yat-sen university, Guangzhou 510080, China
  • Received:2008-08-12 Published:2008-12-01
  • Corresponding author: Ren-bin LIU
引用本文:

王佳妮, 刘仁斌, 梁惠珍, 周兴华, 王深明. 乳腺癌组织中HER2、ERα、ERβ、PR的表达及其相关性分析[J/OL]. 中华普通外科学文献(电子版), 2008, 02(06): 34-37.

Jiani WANG, Ren-bin LIU, Hui-zhen LIANG, Xing-hua ZHOU, Shen-ming WANG. Expression of HER2, ERα, ERβ and PR in breast cancer and their clinical significance[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2008, 02(06): 34-37.

目的

探讨雌激素受体α(ERα)、雌激素受体β(ERβ)、孕激素受体(PR)、人类表皮生长因子受体2(HER2)在乳腺癌组织中的表达及其与TNM分期和腋窝淋巴结状况的关系。

方法

随机选择我院在2004年12月至2007年12月收治的HER2高表达(+++)51例与无表达(-)53例乳腺浸润性导管癌病例,分别检测乳腺癌组织的ERα、ERβ、PR的表达水平,分析其与TNM分期、腋窝淋巴结转移等临床指标的相关性。

结果

104例乳腺癌患者,TNM分期为I期的占14.42%,II期占62.50%,III期占19.23%,IV期占3.85%;HER2阳性的淋巴结转移率为41.18%,HER2阴性的转移率为47.5%;ERα、ERβ、PR的阳性表达率分别为52.88%、63.46%、73.08%。ERβ与ERα、PR的表达呈正相关(P<0.01),与HER2的表达负相关(P<0.01);ERα与PR的表达正相关(P<0.01),与HER2负相关(P<0.01),PR与HER2的表达负相关(P<0.05);ERα、ERβ、PR、HER2的表达与淋巴结转移情况及TNM分期无显著相关性。

结论

HER2作为乳腺癌预后不良的重要指标与作为乳腺癌预后良好的重要指标ERα、ERβ、PR的表达呈负相关,与TNM分期及腋窝淋巴结转移状态未显示明显相关性。

Objective

Investigate the expression of estrogen receptor α (ERα),estrogen receptor β(ERβ),progesterone receptor(PR),human epithelial growth factor receptor 2(HER2)in breast cancer and their relationship with TNM stage and lymph node metastasis.

Methods

51 HER2(+++)cases and 53 HER2(-)cases were randomly selected in our hospital from Dec 2004 to Dec 2007,and were detected for the expressions of ERα,ERβand PR respectively,then their relationship with TNM stage and lymph node metastasis were analyzed.

Results

Of all of 104 cases of breast cancer,the ratios of different stages were 14.42% (stage I),62.50% (stage II),19.23%(stage III)and 3.85%(stage IV)respectively.The positive rate of lymph node metastasis in the HER2(+++)patients was 41.18%,and in HER2 (-)patients was 47.5%.The positive rates of ERα,ERβ,and PR were 52.88%,63.46%,73.08%respectively.The expression of ERβ was positively correlated with ERα and PR (P<0.01)and negatively correlated with HER2(P<0.01).The expression of ERα was positively correlated with PR(P<0.01)and negatively correlated with HER2(P<0.01).The expression of PR was negatively correlated with HER2(P<0.05).The expression of ERα,ERβ,PR and HER2 were irrelevant with TNM stages and lymph node metastasis.

Conclusion

As the good prognostic markers,ERα,ERβ,PR have negative correlation with the expression of HER2,an unfavorable prognostic marker,which shows no correlation with TNM stages and lymph node metastasis.

表1 HER2 与临床病理学指标状况(104 例)
表2 各临床病理学指标的Spearman 相关性分析(相关系数r
1
Kuiper GG,Enmark E,Peltohuikko M,et al.Cloning of a novel receptor expressed in rat prostate and ovary.Proc Natl A cad Sci USA,1996,93(12):5925-5930.
2
Lange CA, Richer JK, Shen T, et al. Convergence of progesterone and epidermal growth factor signaling in breast cancer.J Biol Chem, 1998,273(47):31308-31316.
3
Disis ML,Schiffman K.Cancer vaccines targeting the HER2/neu oncogenic protein.Sem in Oncol,2001,28(6 Suppl 18):12-20.
4
Têtu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer.The influence of the pattern of immunostaining and adjuvant therapy. Cancer, 1994, 73(9): 2359-2365.
5
Menard S,Papa SM,Campiglio M,et al.Biologic and therapeutic role of HER2 in cancer.Oncogene,2003,22(42):6570-6578.
6
Tagliabue E, Agresti R, Ghirelli C, et al. The early relapse of premenopausal patients after surgery for node-positive breast carcinoma.Breast Cancer Res Treat,2001,70(2):155-156.
7
沈镇宙, 邵志敏. 乳腺肿瘤学. 上海: 上海科学技术出版社,2004.393.
8
Kunisue H,Kurebayashi J,Otsuki T,et al.Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer,2000,82(1):46-51.
9
Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol, 2003,200(3):290-297.
10
Chung YL,Sheu ML,Yang SC,et al.Resistance to tamoxifen-induced apoptosis ins associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.Int J Cancer,2002,97(3):306-312.
11
Dowsett M,Harper-Wynne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor positive primary breast cancer.Cancer Res,2001,61(23):8452-8458.
12
Houslon SJ,Plunkell TA,Barnes DM,et al.Overexpression of HER-2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.Br J Cancer,1999,79(7-8):1220-1226.
13
Mosselman S, Ploman J, Djkema R. ERβ: indentification and characterisation of a novel human estrogen receptor.FEBS Lett,1996,392(1):49-53.
14
Fuqua SA,Schiff R,Parra I.Estrogen receptor beta protein in human breast cancer:correlation with clinical tumor parameters.Cancer Res,2003,63(10):2434-2439.
15
Speirs V,Parkes AT,Kerin MJ.Coexpression of estrogen receptor alpha and beta:poor prognostic factors in human breast Cancer?Cancer Res,1999,59(3):525-528.
16
Park BW,Kim KS,Heo MK,et al.Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis?Breast Cancer Res Treat,2003,80(1):79-85.
17
Omoto Y,Inoue S,Ogawa S,et al.Clinical value of the wild-type estrogen receptor beta expression in breast cancer.Cancer Letters,2001,163(2):207-212.
18
Poola I, Clarke R, DeWitty R, et al. Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles inbreast tumors of Caucasian women.Cancer,2002,94(3):615-623.
19
Lazennec G,Bresson D,Lucas A,et al.ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology, 2001, 142(9): 41 20-4130.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 杨柳, 宋振川, 王新乐. 乳腺癌改良根治术联合背阔肌复位的临床疗效评估[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 269-273.
[5] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[6] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[7] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[8] 唐丹萍, 王萍, 江孟蝶, 杨晓蓉. 自体脂肪移植在乳腺癌术后乳房重建的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 582-585.
[9] 刘先勇, 秦东梅, 张若梅, 李俊娇, 孟春芹, 邬明歆, 王玉红, 赵新鲜, 徐瑞联, 洪文文, 马玲, 仇玮, 周宇. Her2/Hes1在肠型胃癌Correa级联反应3个病理阶段中的表达及意义[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 321-327.
[10] 黄程鑫, 陈莉, 刘伊楚, 王水良, 赖晓凤. OPA1 在乳腺癌组织的表达特征及在ER阳性乳腺癌细胞中的生物学功能研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 275-284.
[11] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要